Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

General criteria (all participants):

• People who, in the investigator's opinion, are able to understand and follow the study requirements
• People living independently in the community or in an assisted-living facility where they are mainly responsible for their own daily care
• People who are able to give written consent before the study begins
• Women who cannot become pregnant — including those who have had a hysterectomy, removal of both ovaries or both fallopian tubes, have not yet started their period, or are post-menopausal
• Women who can become pregnant, provided they have used reliable contraception from one month before the first vaccine dose, agree to continue contraception for at least one month after the last dose, and have a negative pregnancy test on the day of the first vaccination
• People with ongoing medical conditions, with or without treatment, that the investigator considers to be medically stable

Group 1 (blood cancer):

• Adults aged 18 or older who have been diagnosed with multiple myeloma (including early-stage) or lymphoma, and whose condition is considered stable by the investigator
• People who have not had a stem cell transplant, or who are at least 3 months past an autologous (own cells) stem cell transplant and no more than 24 months after it — or more than 24 months after transplant if still receiving immune-suppressing treatment
• People taking immune-suppressing or immune-modifying medications related to their blood cancer condition

Group 2 (lung cancer):

• Adults aged 18 or older diagnosed with lung cancer at stage 1 or higher
• People currently receiving cancer treatment (such as chemotherapy or immunotherapy), or who are due to start treatment within 14 days, with vaccinations preferably scheduled between treatment cycles

Group 3 (autoimmune or chronic inflammatory disease):

• Adults aged 18 or older diagnosed with inflammatory bowel disease or rheumatoid arthritis
• People currently being treated with biologics such as TNF-alpha blockers, anti-CD20 therapies, JAK inhibitors, or similar biological treatments (combinations with other medications such as DMARDs, anti-inflammatory drugs, or steroids are also allowed)
• People whose condition is stable at the time of entering the study

Group 4 (healthy older adults):

• Adults aged 60 or older who are considered healthy based on their medical history, with stable or well-managed chronic conditions such as diabetes, high blood pressure, or heart disease permitted

Who may not be able to join:

• Women who can become pregnant but have not used adequate contraception from one month before the first vaccination
• Women who can become pregnant but have a positive or untested pregnancy result on the day of the first vaccination
• People whose chronic medical condition is not considered medically stable by the investigator
• People in Group 1 who are between 0 and 3 months after an autologous stem cell transplant, or more than 24 months post-transplant without ongoing immune-suppressing treatment (confirm with trial site)
• People in Group 2 whose lung cancer is below stage 1, or who are not on or about to start cancer treatment (confirm with trial site)
• People in Group 3 who do not have inflammatory bowel disease or rheumatoid arthritis, or who are not on the specified biological treatments
• People in Group 4 who are under 60 years of age

Important: Always verify eligibility with the trial site directly before applying.